Point72 Hong Kong’s Citius Pharmaceuticals CTXR Stock Holding History

Point72 Hong Kong’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-837	Closed	-$73K	–	2054
2021 Q2	$73K	Buy	+837	New	+$50.3K	﹤0.01%	1390

Other funds holding CTXR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Point72 Hong Kong's CTXR Position: Q3 2021 in Review

Point72 Hong Kong sold out of Citius Pharmaceuticals (CTXR) in Q3 2021, closing a stake of 837 shares — an estimated $73K sold.

Point72 Hong Kong first reported a position in CTXR in Q2 2021 and held it in 1 quarter. The position peaked at $73K in Q2 2021. 71 funds tracked by Wall St. Rank hold CTXR as of Q3 2021.

Point72 Hong Kong reported no remaining Citius Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Point72 Hong Kong sold 837 Citius Pharmaceuticals shares in Q3 2021, an estimated $73K.
Point72 Hong Kong first reported a position in Citius Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Point72 Hong Kong's Citius Pharmaceuticals position peaked at $73K in Q2 2021.
71 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2021.

Based on Point72 Hong Kong's 13F filing for Q3 2021, filed 15 Nov 2021.